1. Engaging Adaptable Hybrid
Ecosystems to commercialize
nascent technologies-
A perspective on
Nanobiotechnology
commercialization
Bhuvaneashwar Subramanian, Program Manager,
Healthcare and Life SciencesVertical Intelligence Practice
Global Analytics, Corporate Strategy and Alliances
Hewlett Packard Company
Email : bhuvaneashwar.subramanian@hp.com
2. Key Themes Covered
Innovation Ecosystems andTheir
Limitations in Theory
Introduction to the AHE theory
The Nanobiotechnology Example
Assessment of ecosystems across US,
Australia and Malaysia
Future Directions
4. Innovation ecosystems :An organized system of
actors and agencies aimed at facilitating innovation
through dynamic exchange of knowledge
Governments
AcademiaIndustry
Individual
Organizations
Nations
People
Industries
5. Current models of innovation focus myopically on
improving the competitive advantage of nations
MODEL 1: NATIONAL INNOVATION SYSTEMS(NIS)
Policy
• Driven by
governments
Structure
• Core
Environments
• Supporting
Entities
• Knowledge
Flows
Objective
• Improving
economic
performance
through
regional
innovation
activity
6. Current models of innovation focus myopically on
improving the competitive advantage of nations
MODEL 2:TRIPLE HELIX MODEL(THM)
Policy
• Primarily
driven by
universities
through tech
licensing and
spinoffs
Structure
• University
driven
• Collaboration
between
three
institutions
• Alternative
positioning
approaches
Objective
• Create a
knowledge
based society
to improve
regional
economic
performance
7. Existing innovation models are
challenged on three fronts-
Localization of Resources
NIS focuses on localization of resources
THM does not discuss how interchangeability of resources could
occur
Lack of Pervasiveness
Both theories do not sufficiently address the pervasiveness of the
ecosystems outside national boundaries
Adaptability to Changing Innovation Dynamics
The theories do not suitably provide for trends such as reverse
innovation, open innovation and crowdsourcing
9. The Adaptable Hybrid EcosystemTheory Builds on
These Challenges to fundamentally call out -
An inclusive innovation
environment that is sustained by
dynamic and evolutionary
interactions between temporal
global alliances of industry,
academia and universities, guided
by the facilitatory powers of
governments through bilateral
agreements
10. The theory implies 4 fundamental
paradigm shifts that encompass the
wave of globalization
View Global
Consumers
as Need
Based
Clusters
Viewing
Regions as
Centers of
Competence
and Markets
Coexistence
of multiple
innovation
models
1 2
3
Governments as Facilitators
4
12. Nanobiotechnology :A convergence of
nanotechnology and biotechnology
Atomic Force
Microscopy
Targeted Cancer
Therapeutics
(paclitaxel,
abraxane)
Drug Delivery
MEMS based
molecular
diagnostics
13. A view of the nanobiotechnology market and challenges
US$19Bn
in 2012
US$200Mn/yr
To the NNI
65%
20%
15%
Intellectual Investment
United States
Europe
Rest of World
40
Nanobio-
technology
products
14. Key Challenges for the Industry
• FDA approval of
nanobiotechnology
products is stringent and is
mostly driven towards
topical applications
•Nascent nature of the field
shows poor proof of
concepts and cross
application of patents
across other disciplines
prevents
commercialization
•Venture capitalists are
looking for quick exit only
to recover investments
after first technology
licensing
•Less than 40 products
commercialized
•Limited engagement with
big pharma
Lack of
suitable
technology
transfer
initiatives
Lack of
sustained
venture
capital
interest
Regulatory
and socio-
ethical
concerns
Lack of
sufficient
proof of
concepts and
patent wars
16. Instances ofVarious Paradigms of AHE play out across
nanobiotechnology commercialization activities across
US,Australia and Malaysia
Viewing Customers as Need Based Clusters1
Nanomedicine Roadmap Initiative in
collaboration with Private Pharma Majors
Open Innovation Initiatives to facilitate
drug discovery and development including
nanodrug delviery systems
Gamification platforms to address protein
folding challenges on a global scale
United States
of America
17. Paradigm Shift Implications for the AHE in US,
Malaysia and Australia
Regions as Centers of Competence
and Markets
2
MALAYSIA AUSTRALIA
MOSTI Invests US$800 Million
for leveraging competence in
nanotechnology for MEMS design
Collaboration with US leading to
FDI of US$45 Billion for tech
know how and training
US$1 billion investment into the
Biotech Cluster in Malaysia by
Pharma and Life Sciences Majors
to develop therapeutics and
reach out to the APJ region
Australian and EU collaboration
program-FEAST for nanobio
research and commercialization
Collaboration between private
entities in Australia and China for
technology commercialization
18. Paradigm Shift Implications for the AHE in US,
Malaysia and Australia
Multiple Innovation Models Dependent Upon
Business Need and Maturity
3
Formation of Precompetitive Alliances such as the Nanomedicines
Alliance for rapid nanobiotherapeutic commercialization
Technology licensing agreements between nanotechnology startups
and pharma majors for molecular diagnostics
19. Paradigm Shift Implications for the AHE in US,
Malaysia and Australia
Governments as Facilitators of Innovation4
International Dialogue on Responsible Research and Development
of Nanotechnology,
Foresight Guidelines on Molecular Nanotechnology
International Consensus Standards
TheAustralia Group have engaged separately in formal and informal
ways, to facilitate international policies for regulation of
nanotechnology
The facilitation is dynamic ranging from clear directive focussed to
creating environments and engaging as an advisor based on the
maturity of the industry
UNITED STATES , EU & AUSTRALIA
20. Structured and Unstructured Environments Equally
Facilitate Commercialization of Nanobiotechnology
UNITED STATES AUSTRALIA MALAYSIA
• Central Governance
(NNI)
• Industry Consortium
Driven
• Industry Consortium
• Driven+Government
Driven
• Government directs
programs
•Drives International Risk
management collaborations
for commercialization through
IRC
•Government serves as a
facilitator with focus
only on creating awarness
on safety aspects.
• Government plays an
advisory role that
handholds until certain
time of maturity
• NNI and NIH run
competitive grant
programs for international
collaborative projects and
SME development.
• Private sector focused on
international linkages for
innovation
• ARC and ARCNN
facilitate international
research collaborations in
nanobiotech
• Autonomous industry
bodies such as ANA and
ANMA facilitate industry
linkages and
collaborations
• MOSTI facilitates
collaborations and HRD
development
• Industry bodies such as
BiotechCorp engage in
partnering with global
players in biotechnology
and nanobiotechnology
21. Conclusion
The AHE model offers a perspective on how
nascent technologies could be commercialized
across global boundaries
It explores the possibilities of driving innovation
by addressing key paradigm shifts that serve as
pillars for its implementation
22. Next Steps
Research is needed to understand how
knowledge flows across the entities may be
governed so as to address the paradigms
discussed
Research on impact of open innovation and
new business models on knowledge flows
and capacity development for innovation
ecosystems in emerging markets
Viability of new business models and
penetration of paradigms in emerging
markets
23. THANK YOU
You can reach me at :
bhuvaneashwar.subramanian@hp.com
or
eashwarsubramanian@gmail.com
